Located in the heart of Uruguay and fully licensed, GreenMed is more than a cannabis processing company, it is an institution committed to the highest pharmaceutical standards, standing out as a reference in the South American region.  

GMP: Quality and Safety Guarantee

What sets GreenMed apart is the pursuit of excellence and specialization in the production of cannabis-based products with a high pharmaceutical standard, focusing primarily on its commitment to Good Manufacturing Practices (GMP), a set of standards that ensure the quality, safety, and efficacy of its inputs.  

The company's CEO, Ignacio Bussy, explains that: “with an initial investment of over 21 million dollars, approximately 106 million reais, the goal is to meet the various sector regulations, serving as a production hub in Latin America and worldwide.”

Currently, the company holds the Uruguayan Good Manufacturing Practices (GMP) certificate, approval from the National Health Surveillance Agency (Anvisa), and is in the final stages of obtaining the European GMP certificate, the world's strictest standard for the pharmaceutical industry.  

By strictly adhering to these standards, the company ensures consistently effective, high-quality, and standardized products, essential to gain the trust of patients, physicians, pharmaceutical industries, and other stakeholders in this sector.

"At GreenMed, every stage of the process is meticulously controlled to ensure excellence in quality and safety, which is ensured by state-of-the-art equipment, facilities designed by specialized architecture firms, and built to the most demanding construction standards in the pharmaceutical industry,” highlights Bussy.

Regulation in Uruguay

With pioneering legislation, where all uses of cannabis were allowed in 2013, Uruguay has become a regulatory reference for other countries, highlights Leandro Villalba, the company's technical director:

“With regulation, Uruguay can finally define what can and cannot be done within the sector, and this pioneering spirit has served as an example for countries like Canada, South Africa, and the USA itself.”

Meeting Market Needs  

In addition to its pursuit of excellence and compliance with regulatory rules, GreenMed is strategically positioned to meet the demands of the global market. With its structure and production capacity, the company has all the conditions to provide high-quality products to players worldwide, ensuring, through its operations, a high pharmaceutical standard from seed to patient.  

“Genetic selection, certified cultivation, controlled environment drying process, and supercritical CO2 extraction methods place the company in a privileged position in the market, after all, it is rare to see a structure of this standard that meets all GMP requirements,” says Javier Jarak, COO of GreenMed.  

Ongoing Innovation and Development

At GreenMed, innovation is a priority. The company invests significant resources in research and development, dedicating itself to the development of new strains, processes, and formulations to meet customer needs and drive the market.

"We are committed to constantly driving the cannabis industry, creating products that not only meet but exceed our customers' expectations. Here, we shape the future of health and well-being with products that are truly of high pharmaceutical standard", concludes Jarak.  

With its commitment to quality, its strategic position in South America, and its innovative vision for the future, GreenMed is prepared to lead the way in the production and enhancement of cannabis-based products, even on a global scale.